Breathe Well Live Well
|
Dynavax, AstraZeneca Amend Deal for Asthma Candidate
Zacks.com As per the amended agreement, AstraZeneca will now be responsible for conducting a phase IIa safety and efficacy trial on candidate AZD1419 in asthma patients. The study was originally decided to be conducted by Dynavax. The companies had earlier … |
View full post on asthma – Google News
|
Dynavax & AstraZeneca Alter Agreement for Asthma Product
Yahoo News As per the agreement, AstraZeneca will now provide full funding while Dynavax will conduct a phase IIa safety and efficacy trial on pipeline candidate AZD1419 in asthma patients. Dynavax plans to initiate the study in the first half of 2015. The … |
View full post on asthma – Google News
|
Dynavax Technologies Corporation (DVAX): Dynavax Initiates Phase I Trial In …
Seeking Alpha After the close of the markets on Wednesday, October 9, 2013, Dynavax (DVAX) announced it will begin dosing patients in the first human trial in its asthma program. The trial, which is being conducted under a collaborative agreement with AstraZeneca … |
View full post on asthma – Google News
|
Dynavax starts Phase I trial of asthma treatment
San Francisco Business Times (blog) The Berkeley company (NASDAQ: DVAX) will enroll up to 45 people in this Phase I trial of AZD1419, an inhaled TLR9 agonist. These pioneering patients will all be healthy, and they'll get either the drug in ascending doses or a placebo. If all goes well, … DYNAVAX TECHNOLOGIES CORPORATION : Dynavax Initiates First Human … Dynavax Initiates First Human Trial in Asthma Program |
View full post on asthma – Google News
|
DYNAVAX TECHNOLOGIES CORPORATION : Dynavax Initiates First Human …
4-traders (press release) BERKELEY, CA — (Marketwired) — 10/09/13 — Dynavax Technologies Corporation (NASDAQ: DVAX) announced today the start of dosing in the first human clinical trial in its asthma program. Dynavax is conducting the trial under its collaboration agreement … Dynavax starts Phase I trial of asthma treatment Dynavax Initiates First Human Trial in Asthma Program |
View full post on asthma – Google News
|
Dynavax Technologies to commence Phase I asthma studies
Equities.com Comtex News Network. Nov 02, 2012 (Datamonitor via COMTEX) — Dynavax Technologies Corporation, a biopharmaceutical company, has announced that it will advance AZD1419, a second-generation TLR-9 agonist for asthma, into Phase I clinical studies. |
View full post on asthma – Google News
|
Dynavax Advances Agonist For Asthma Into The Clinic
Seeking Alpha Dynavax Technologies Corporation (DVAX) announced this morning it will advance its proprietary second-generation TLR-9 agonist for asthma into Phase 1 clinical studies. The work will be performed under the terms of a collaboration with AstraZeneca … Dynavax to Initiate Phase 1 Studies for TLR-9 Agonist for Asthma |
View full post on asthma – Google News
|
Dynavax to Initiate Phase 1 Studies For TLR-9 Agonist For Asthma
Benzinga Dynavax Technologies Corporation (NASDAQ: DVAX) announced today that it will advance AZD1419, a proprietary second-generation TLR-9 agonist for asthma, into Phase 1 clinical studies. Development expenses will be fully funded by AstraZeneca under … |
View full post on asthma – Google News
|
Dynavax and AstraZeneca Agree to Conduct Toxicology Studies for TLR-9 Agonist …
Healthcare Global (press release) These include demonstration that AZD1419 is capable of producing long lasting disease-modifying effects in a mouse model of atopic asthma. Under the terms of the amended 2006 research collaboration and license agreement, AstraZeneca will provide to … |
View full post on asthma – Google News
|
Dynavax and AstraZeneca Agree to Conduct Toxicology Studies for TLR-9 Agonist …
MarketWatch (press release) These include demonstration that AZD1419 is capable of producing long lasting disease-modifying effects in a mouse model of atopic asthma. Under the terms of the amended 2006 research collaboration and license agreement, AstraZeneca will provide to … |
View full post on asthma – Google News